Product information and disease descriptionProduct descriptionProduct information
Dosing and administration
6 evidence topics · 5 sources
Azetukalner (XEN1101)
Focal onset seizures
- Manufacturer
- Xenon Pharmaceuticals
- Regulatory submission
- NDA submitted September 2026
- Launch
- Not announced
- Last updated